Author:
Cai ZhuYing,Yang Wei,He YingYing,Chen Qingge,Wang ShiQiang,Luo Xuming,Wang Xiongbiao
Funder
Shanghai University of Traditional Chinese Medicine, “085”project
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Cohen MS, Washton HE, Barranco SF. Multicenter clinical trial of cefoperazone sodium in the United States. Am J Med. 1984;77(1B):35–41.
2. Bailey RR, Peddie B, Blake E, Bishop V, Reddy J. Cefoperazone in the treatment of severe or complicated infections. Drugs. 1981;22(Suppl 1):76–86.
3. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
4. Greenberg RN, Reilly PM, Weinandt WJ, Bollinger M, Kennedy DJ. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation. Clin Ther. 1987;10(1):52–6.
5. Koga H, Tomono K, Hirakata Y, Kohno S, Abe K, Kawamoto S, et al. Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase. Jpn J Antibiot. 1996;49(8):800–7.